CRSP vs. MNTA, NVAX, ALLO, FATE, ADVM, NBIX, TECH, QGEN, PCVX, and RVMD
Should you be buying CRISPR Therapeutics stock or one of its competitors? The main competitors of CRISPR Therapeutics include Momenta Pharmaceuticals (MNTA), Novavax (NVAX), Allogene Therapeutics (ALLO), Fate Therapeutics (FATE), Adverum Biotechnologies (ADVM), Neurocrine Biosciences (NBIX), Bio-Techne (TECH), Qiagen (QGEN), Vaxcyte (PCVX), and Revolution Medicines (RVMD). These companies are all part of the "medical" sector.
CRISPR Therapeutics (NASDAQ:CRSP) and Momenta Pharmaceuticals (NASDAQ:MNTA) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, community ranking, institutional ownership, risk, profitability, media sentiment, valuation, analyst recommendations and earnings.
CRISPR Therapeutics currently has a consensus price target of $75.71, indicating a potential upside of 30.72%. Given CRISPR Therapeutics' higher probable upside, equities research analysts plainly believe CRISPR Therapeutics is more favorable than Momenta Pharmaceuticals.
In the previous week, CRISPR Therapeutics had 5 more articles in the media than Momenta Pharmaceuticals. MarketBeat recorded 5 mentions for CRISPR Therapeutics and 0 mentions for Momenta Pharmaceuticals. CRISPR Therapeutics' average media sentiment score of 0.61 beat Momenta Pharmaceuticals' score of 0.00 indicating that CRISPR Therapeutics is being referred to more favorably in the media.
CRISPR Therapeutics has higher revenue and earnings than Momenta Pharmaceuticals. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Momenta Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
CRISPR Therapeutics has a net margin of 0.00% compared to Momenta Pharmaceuticals' net margin of -757.61%. CRISPR Therapeutics' return on equity of -11.56% beat Momenta Pharmaceuticals' return on equity.
69.2% of CRISPR Therapeutics shares are owned by institutional investors. 4.1% of CRISPR Therapeutics shares are owned by company insiders. Comparatively, 3.4% of Momenta Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
CRISPR Therapeutics has a beta of 1.7, indicating that its share price is 70% more volatile than the S&P 500. Comparatively, Momenta Pharmaceuticals has a beta of 1.71, indicating that its share price is 71% more volatile than the S&P 500.
Momenta Pharmaceuticals received 105 more outperform votes than CRISPR Therapeutics when rated by MarketBeat users. Likewise, 66.59% of users gave Momenta Pharmaceuticals an outperform vote while only 65.49% of users gave CRISPR Therapeutics an outperform vote.
Summary
CRISPR Therapeutics beats Momenta Pharmaceuticals on 13 of the 17 factors compared between the two stocks.
Get CRISPR Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRSP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CRSP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
CRISPR Therapeutics Competitors List
Related Companies and Tools
